It's an open forum for Indian Clinical and Hospital Pharmacists to discuss on designing, implementing, and monitoring a therapeutic plan that will produce specific therapeutic outcomes for the patient Eg:Antibiotic Policies, Pharmacist Interventions, Medication Therapy Management. DRP,s and Its Management.
Forum rules: Dear User, Kindly read our forum rules before you proceed with our PharmD Info, Your first 5 posts/topics requires moderator approval and this website is purely meant for educational and knowledge sharing purpose only so you should not make any topics/replies/messages which criticize, threaten or abuse any member, pharmacy governing bodies and organizations. Your post will be deleted automatically by our BB Pruning System if your topic is not viewed by members for more than 5 days. So, make sure that your topics and its related contents are unique and valuable. We expect you to be an active member of our forum to continue with your free membership.Kindly note that if a member received more than five warnings from moderator/members they will be blocked automatically by our Bulletin Board system.
CDER Drug Safety Priorities 2015-2016 details both the Center’s key safety priorities as well as the depth and versatility of drug safety initiatives across CDER and the FDA. The report includes program updates and milestones achieved since the start of 2015, describing several of the FDA’s most important efforts in drug safety science, surveillance, and oversight. The report seeks to offer a broad picture of current safety efforts, and highlights the critical advantages gained in safety science through a range of multidisciplinary collaborations and partnerships—within CDER and across the FDA, and with stakeholders from other government agencies, patient communities, industry, and academia.
To download the Drug safety priorities-2015-16 follow the below link after your registration with PharmD Info Forum.